Literature DB >> 24349237

Procalcitonin levels predict acute kidney injury and prognosis in acute pancreatitis: a prospective study.

Hua-Lan Huang1, Xin Nie1, Bei Cai1, Jiang-Tao Tang1, Yong He1, Qiang Miao1, Hao-Lan Song1, Tong-Xing Luo1, Bao-Xiu Gao1, Lan-Lan Wang1, Gui-Xing Li1.   

Abstract

BACKGROUND: Acute kidney injury (AKI) has been proposed as a leading cause of mortality for acute pancreatitis (AP) patients admitted to the intensive care unit (ICU). This study investigated the predictive value of procalcitonin (PCT) for AKI development and relevant prognosis in patients with AP, and compared PCT's predictive power with that of other inflammation-related variables.
METHODS: Between January 2011 and March 2013, we enrolled 305 cases with acute pancreatitis admitted to ICU. Serum levels of PCT, serum amyloid A (SAA), interleukin-6 (IL-6), and C reactive protein (CRP) were determined on admission. Serum PCT was tested in patients who developed AKI on the day of AKI occurrence and on either day 28 after occurrence (for survivors) or on the day of death (for those who died within 28 days).
RESULTS: Serum PCT levels were 100-fold higher in the AKI group than in the non-AKI group on the day of ICU admission (p<0.05). The area under the receiver-operating characteristic (ROC) curve of PCT for predicting AKI was 0.986, which was superior to SAA, CRP, and IL-6 (p<0.05). ROC analysis revealed all variables tested had lower predictive performance for AKI prognosis. The average serum PCT level on day 28 (2.67 (0.89, 7.99) ng/ml) was significantly (p<0.0001) lower than on the day of AKI occurrence (43.71 (19.24,65.69) ng/ml) in survivors, but the serum PCT level on death (63.73 (34.22,94.30) ng/ml) was higher than on the day of AKI occurrence (37.55 (18.70,74.12) ng/ml) in non-survivors, although there was no significant difference between the two days in the latter group (p = 0.1365).
CONCLUSION: Serum PCT is superior to CRP, IL-6, and SAA for predicting the development of AKI in patients with AP, and also can be used for dynamic evaluation of AKI prognosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24349237      PMCID: PMC3862675          DOI: 10.1371/journal.pone.0082250

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  47 in total

1.  Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery.

Authors:  Jaya Mishra; Catherine Dent; Ridwan Tarabishi; Mark M Mitsnefes; Qing Ma; Caitlin Kelly; Stacey M Ruff; Kamyar Zahedi; Mingyuan Shao; Judy Bean; Kiyoshi Mori; Jonathan Barasch; Prasad Devarajan
Journal:  Lancet       Date:  2005 Apr 2-8       Impact factor: 79.321

2.  Prospective evaluation of the risk of serious bacterial infection in children who present to the emergency department with hyperpyrexia (temperature of 106 degrees F or higher).

Authors:  Barbara W Trautner; A Chantal Caviness; Gary R Gerlacher; Gail Demmler; Charles G Macias
Journal:  Pediatrics       Date:  2006-07       Impact factor: 7.124

3.  Sepsis in European intensive care units: results of the SOAP study.

Authors:  Jean-Louis Vincent; Yasser Sakr; Charles L Sprung; V Marco Ranieri; Konrad Reinhart; Herwig Gerlach; Rui Moreno; Jean Carlet; Jean-Roger Le Gall; Didier Payen
Journal:  Crit Care Med       Date:  2006-02       Impact factor: 7.598

4.  Serial procalcitonin responses in infection of children with secondary immunodeficiency.

Authors:  M Hatzistilianou; A Rekleity; F Athanassiadou; M A DeLutiis; P Conti; D Catriu
Journal:  Clin Invest Med       Date:  2007       Impact factor: 0.825

Review 5.  The Atlanta Classification of acute pancreatitis revisited.

Authors:  T L Bollen; H C van Santvoort; M G Besselink; M S van Leeuwen; K D Horvath; P C Freeny; H G Gooszen
Journal:  Br J Surg       Date:  2008-01       Impact factor: 6.939

Review 6.  Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review.

Authors:  S G Coca; R Yalavarthy; J Concato; C R Parikh
Journal:  Kidney Int       Date:  2007-12-19       Impact factor: 10.612

7.  Acute renal failure in patients with severe sepsis and septic shock--a significant independent risk factor for mortality: results from the German Prevalence Study.

Authors:  Michael Oppert; Christoph Engel; Frank-Martin Brunkhorst; Holger Bogatsch; Konrad Reinhart; Ulrich Frei; Kai-Uwe Eckardt; Markus Loeffler; Stefan John
Journal:  Nephrol Dial Transplant       Date:  2007-12-07       Impact factor: 5.992

8.  Routes of spread of pathogens into the pancreas in a feline model of acute pancreatitis.

Authors:  A L Widdison; N D Karanjia; H A Reber
Journal:  Gut       Date:  1994-09       Impact factor: 23.059

9.  Acute renal failure in patients with sepsis.

Authors:  José António Lopes; Sofia Jorge; Cristina Resina; Carla Santos; Alvaro Pereira; José Neves; Francisco Antunes; Mateus Martins Prata
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

10.  Early acute kidney injury and sepsis: a multicentre evaluation.

Authors:  Sean M Bagshaw; Carol George; Rinaldo Bellomo
Journal:  Crit Care       Date:  2008-04-10       Impact factor: 9.097

View more
  18 in total

1.  AKI Associated with Acute Pancreatitis.

Authors:  Tareq I Nassar; Wajeh Y Qunibi
Journal:  Clin J Am Soc Nephrol       Date:  2019-05-22       Impact factor: 8.237

2.  Serum Procalcitonin in Patients with Acute Liver Failure.

Authors:  Takaaki Sugihara; Masahiko Koda; Toshiaki Okamoto; Kenichi Miyoshi; Tomomitsu Matono; Kenji Oyama; Keiko Hosho; Jun-Ichi Okano; Hajime Isomoto
Journal:  Yonago Acta Med       Date:  2017-03-09       Impact factor: 1.641

3.  Plasma Neutrophil Gelatinase-Associated Lipocalin Is Primarily Related to Inflammation during Sepsis: A Translational Approach.

Authors:  Gordon P Otto; Jorge Hurtado-Oliveros; Ha-Yeun Chung; Kristin Knoll; Thomas Neumann; Hans J Müller; Marco Herbsleb; Matthias Kohl; Martin Busch; Maik Sossdorf; Ralf A Claus
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

4.  Inflammatory mediators in the diagnosis and treatment of acute pancreatitis: pentraxin-3, procalcitonin and myeloperoxidase.

Authors:  Osman Simsek; Ahmet Kocael; Pınar Kocael; Anıl Orhan; Mahir Cengiz; Huriye Balcı; Kenan Ulualp; Hafize Uzun
Journal:  Arch Med Sci       Date:  2018-02-21       Impact factor: 3.318

5.  Serum Urokinase-Type Plasminogen Activator Receptor Does Not Outperform C-Reactive Protein and Procalcitonin as an Early Marker of Severity of Acute Pancreatitis.

Authors:  Witold Kolber; Beata Kuśnierz-Cabala; Paulina Dumnicka; Małgorzata Maraj; Małgorzata Mazur-Laskowska; Michał Pędziwiatr; Piotr Ceranowicz
Journal:  J Clin Med       Date:  2018-09-27       Impact factor: 4.241

6.  A risk score based on procalcitonin for predicting acute kidney injury in COVID-19 patients.

Authors:  Ruo Ran Wang; Min He; Yan Kang
Journal:  J Clin Lab Anal       Date:  2021-05-25       Impact factor: 2.352

Review 7.  Predictive Ability of Procalcitonin for Acute Kidney Injury: A Narrative Review Focusing on the Interference of Infection.

Authors:  Wei-Chih Kan; Ya-Ting Huang; Vin-Cent Wu; Chih-Chung Shiao
Journal:  Int J Mol Sci       Date:  2021-06-27       Impact factor: 5.923

Review 8.  Serum C-reactive protein, procalcitonin, and lactate dehydrogenase for the diagnosis of pancreatic necrosis.

Authors:  Oluyemi Komolafe; Stephen P Pereira; Brian R Davidson; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2017-04-21

Review 9.  Antibiosis of Necrotizing Pancreatitis.

Authors:  Alexander Arlt; Wiebke Erhart; Clemens Schafmayer; Hanns-Christoph Held; Jochen Hampe
Journal:  Viszeralmedizin       Date:  2014-10

10.  Analysis of the diagnostic capabilities of urinary neutrophil gelatinase-associated lipocalin and serum procalcitonin for acute kidney injury at the early stage of critical care intensive care unit admission.

Authors:  Yuji Imoto; Ayano Wakasaki; Kumiko Izumida; Hiroshi Shimada; Kumiko Ohkubo; Yasumasa Kawano; Hiroyasu Ishikura; Akira Matsunaga
Journal:  J Clin Lab Anal       Date:  2021-06-08       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.